What the FDA labels say about taking them together
Abatacept and golimumab
Golimumab's FDA label of September 9, 2025 names abatacept in its drug interactions section; the abatacept label PlainMeds reads does not name golimumab. The golimumab label: “DRUG INTERACTIONS Abatacept: Increased risk of serious infection Anakinra:”
Check it at the source: the abatacept FDA label on DailyMed (effective November 13, 2025, E.R. Squibb & Sons, L.L.C.); the golimumab FDA label on DailyMed (effective September 9, 2025, Janssen Biotech, Inc.).
What does the abatacept label say about golimumab?
Abatacept's label (effective November 13, 2025) does not name golimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ORENCIA), E.R. Squibb & Sons, L.L.C., effective November 13, 2025 (SPL set 0836c6ac-ee37-5640-2fed-a3185a0b16eb), via openFDA; the full label on DailyMed
What does the golimumab label say about abatacept?
Golimumab label, drug interactionsDRUG INTERACTIONS Biologics, including abatacept and anakinra: Increased risk of serious infections ( 5.1 , 5.6 , 5.7 , 5.8 , 7.2 ).
Golimumab label, warnings and precautionsThe concomitant use of a TNF-blocker and abatacept or anakinra was associated with a higher risk of serious infections; therefore, the concomitant use of SIMPONI ARIA and these biologic products is not recommended [see Warnings and Precautions (5.6 , 5.7) and Drug Interactions (7.2) ].
Simponi label (Janssen Biotech, Inc., October 29, 2025), drug interactionsDRUG INTERACTIONS Abatacept: Increased risk of serious infection ( 5.1 , 5.7 , 7.2 ) Anakinra:
Source: FDA drug label (Simponi, BLA125289), Janssen Biotech, Inc., effective October 29, 2025 (SPL set f86cb4a7-c358-4136-ae57-b32bda9bba00), via openFDA
Source: FDA drug label (SIMPONI ARIA), Janssen Biotech, Inc., effective September 9, 2025 (SPL set 9e260a47-55af-4c92-8d88-a86ccc767fff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Abatacept | Golimumab | |
|---|---|---|
| Labeled for | Rheumatoid arthritis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1,469.23 per mL 125 mg/mL syringe | $12,890.32 per mL 50 mg/0.5 mL pen injec |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once